JP2023518153A5 - - Google Patents

Info

Publication number
JP2023518153A5
JP2023518153A5 JP2022547787A JP2022547787A JP2023518153A5 JP 2023518153 A5 JP2023518153 A5 JP 2023518153A5 JP 2022547787 A JP2022547787 A JP 2022547787A JP 2022547787 A JP2022547787 A JP 2022547787A JP 2023518153 A5 JP2023518153 A5 JP 2023518153A5
Authority
JP
Japan
Application number
JP2022547787A
Other languages
Japanese (ja)
Other versions
JP7364315B2 (ja
JPWO2021190622A5 (https=
JP2023518153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/083194 external-priority patent/WO2021190622A1/en
Publication of JP2023518153A publication Critical patent/JP2023518153A/ja
Publication of JP2023518153A5 publication Critical patent/JP2023518153A5/ja
Publication of JPWO2021190622A5 publication Critical patent/JPWO2021190622A5/ja
Priority to JP2023172391A priority Critical patent/JP7827951B2/ja
Application granted granted Critical
Publication of JP7364315B2 publication Critical patent/JP7364315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547787A 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用 Active JP7364315B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172391A JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172391A Division JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Publications (4)

Publication Number Publication Date
JP2023518153A JP2023518153A (ja) 2023-04-28
JP2023518153A5 true JP2023518153A5 (https=) 2023-06-12
JPWO2021190622A5 JPWO2021190622A5 (https=) 2023-06-12
JP7364315B2 JP7364315B2 (ja) 2023-10-18

Family

ID=77891322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547787A Active JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用
JP2023172391A Active JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172391A Active JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Country Status (12)

Country Link
US (2) US11739147B2 (https=)
EP (1) EP4126938A4 (https=)
JP (2) JP7364315B2 (https=)
KR (1) KR102651263B1 (https=)
CN (1) CN115348970B (https=)
AU (2) AU2021240769B2 (https=)
BR (1) BR112022019129A2 (https=)
IL (1) IL296736B2 (https=)
MX (1) MX2022011951A (https=)
PH (1) PH12022552520A1 (https=)
SA (1) SA522440646B1 (https=)
WO (1) WO2021190622A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof
US20260070974A1 (en) * 2021-11-25 2026-03-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-siglec-15 antibody and use thereof
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CA3259231A1 (en) * 2022-06-13 2023-12-21 Shanghai Institute Of Biological Products Co., Ltd. ANTI-SIGLEC15 ANTIBODIES AND THEIR USES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP2013543382A (ja) * 2010-10-05 2013-12-05 第一三共株式会社 破骨細胞関連蛋白質Siglec−15を標的とした抗体
ES2908046T3 (es) 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
EP2832855A4 (en) * 2012-03-30 2016-02-24 Daiichi Sankyo Co Ltd NOVEL ANTI-SIGLEC-15 ANTIBODY
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2015192214A1 (en) * 2014-06-18 2015-12-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
HK1259294A1 (zh) 2015-11-10 2019-11-29 耶鲁大学 用於治疗自身免疫疾病和癌症的组合物及方法
AU2017330346C1 (en) * 2016-09-21 2025-03-06 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof

Similar Documents

Publication Publication Date Title
JP2023518153A5 (https=)
CN305533594S (https=)
CN305532041S (https=)
CN305536655S (https=)
CN305536387S (https=)
CN305536167S (https=)
CN305535350S (https=)
CN305535307S (https=)
CN305535172S (https=)
CN305534895S (https=)
CN305534770S (https=)
CN305533529S (https=)
CN305531769S (https=)
CN305531697S (https=)
CN305531500S (https=)
CN305531161S (https=)
CN305740909S (https=)
CN305529979S (https=)
CN305529950S (https=)
CN305734878S (https=)
CN305527884S (https=)
CN305986682S (https=)
CN305971133S (https=)
CN305952440S (https=)
CN305951565S (https=)